华润双鹤：盐酸吡格列酮分散片获得药品补充申请批准

Core Viewpoint - China Resources Double Crane announced that its subsidiary, Double Crane Tianan Pharmaceutical Co., Ltd., received the approval notice for the supplementary application of Pioglitazone Hydrochloride Dispersible Tablets from the National Medical Products Administration [1] Summary by Categories - Regulatory Approval - The company has received a supplementary application approval for Pioglitazone Hydrochloride Dispersible Tablets from the National Medical Products Administration [1] - Research and Development Investment - As of the date of the announcement, the total R&D investment for this drug's consistency evaluation amounts to RMB 8.8227 million (unaudited) [1]